Kura Oncology, Inc. Stock Analysis & AI Score
Kura Oncology, Inc. (KURA) has an ST Score of 45.3 (C+), driven by its Forecast (A) and held back by its Financial Strength (D+). Analysts rate it Buy with a $23.88 price target (+119.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Kura Oncology, Inc. (KURA) has an ST Score of 45.3 (C+), driven by its Forecast (A) and held back by its Financial Strength (D+). Analysts rate it Buy with a $23.88 price target (+119.9% upside).
- Strongest
- ForecastA
- Weakest
- Financial StrengthD+
All factor grades
- ForecastA
- MomentumA-
- ValuationC-
- GrowthC-
- ProfitabilityD+
- Financial StrengthD+
- Piotroski3/9
Contact
KURA stock: frequently asked questions
What is KURA's ST Score?
Kura Oncology, Inc. (KURA) has an ST Score of 45.3 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is KURA a buy, hold, or sell?
Analysts rate KURA a Buy, with a price target of $23.88 (+119.9% vs the current price). Our ST Score grades it C+ (45.3/100). The ST Score is a data-driven signal, not a recommendation.
What are KURA's factor grades?
Valuation C-, Profitability D+, Financial Strength D+, Momentum A-, Growth C-, Forecast A.
What is KURA's valuation grade?
Kura Oncology, Inc. (KURA) earns a valuation grade of C-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is KURA's growth grade?
Kura Oncology, Inc. (KURA) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is KURA's profitability grade?
Kura Oncology, Inc. (KURA) earns a profitability grade of D+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is KURA's financial strength grade?
Kura Oncology, Inc. (KURA) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for KURA?
The average analyst price target for Kura Oncology, Inc. (KURA) is $23.88 from 17 analysts, which is +119.9% versus the recent price of $10.86.
What is KURA's Piotroski score?
Kura Oncology, Inc. (KURA) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.